Posted by Michael Wonder on 24 Aug 2021
ICER uses observational real world evidence to update 2018 assessment on therapies for hereditary angioedema, finds therapies far less cost effective than earlier estimates
24 August 2021 - Patients initiating therapy in real world dataset had less frequent baseline attack rates than rates from clinical trials used in 2018 assessment; as a result, all three therapies are far less cost effective than earlier estimates and would require a price discount of at least 50% to reach common thresholds of cost effectiveness.
The ICER today published an observational real world evidence update to its 2018 cost effectiveness model of three therapies for long-term prophylaxis against hereditary angioedema attacks: lanadelumab (Takhzyro, Takeda), and two C1 inhibitors (Haegarda, CSL Behring; and Cinryze, Takeda).
